



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



⑪ Publication number: **0 258 404 B1**

⑫

## EUROPEAN PATENT SPECIFICATION

④⑤ Date of publication of patent specification :  
20.05.92 Bulletin 92/21

⑤① Int. Cl.<sup>5</sup>: **G01N 33/569, G01N 33/543,  
C12N 15/00, C12P 21/00,  
C07K 15/00**

②① Application number: 87901921.4

②② Date of filing: 20.02.87

⑥⑥ International application number:  
PCT/US87/00373

⑥⑦ International publication number:  
WO 87/05399 11.09.87 Gazette 87/20

### ⑤④ METHOD OF DETECTING ANTIBODY AGAINST HTLV-III.

③③ Priority: 27.02.86 US 834212

④③ Date of publication of application:  
09.03.88 Bulletin 88/10

④⑤ Publication of the grant of the patent:  
20.05.92 Bulletin 92/21

⑥④ Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

⑤⑥ References cited:  
EP-A- 181 150  
EP-A- 199 438  
US-A- 4 808 536  
WO 86/06099  
CHEMICAL ABSTRACTS, vol. 104, no. 25, 23  
June 1986, Columbus, OH (US); J.GHRAYEB et  
al., p. 170, no. 220096s

⑤⑥ References cited:  
PROCEEDINGS OF THE NATIONAL ACADEMY  
OF SCIENCES OF THE USA, vol. 82, no. 22,  
November 1985, Washington, DC (US);  
D.J.DOWBENKO et al., p. 7748

⑦③ Proprietor: CENTOCOR, INC.  
244 Great Valley Parkway  
Malvern, PA 19355 (US)

⑦② Inventor: CHANG, Nancy, T.  
7405 Brompton  
Houston, TX 77025 (US)  
Inventor: GHRAYEB, John  
3202 Raye Road  
Thorndale, PA 19372 (US)

⑦④ Representative: Holdcroft, James Gerald, Dr.  
et al  
Graham Watt & Co., Riverhead  
Sevenoaks, Kent TN13 2BN (GB)

EP 0 258 404 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent grant. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

## Description

### Field of the Invention

5 This invention is in the fields of immunology and virology and pertains to immunochemical detection of AIDS virus infection based upon recombinant HTLV-III core antigens.

### Background of the Invention

10 Since the identification of human T cell lymphotropic virus Type III (HTLV-III) (also called lymphadenopathy virus (LAV) or AIDS-associated retrovirus (ARV)) as the probable cause of infectious Acquired Immunodeficiency Syndrome (AIDS) and the establishment of a permissive T cell line for mass production of the virus, substantial progress has been made in characterizing the virus. The complete nucleotide sequences of molecular clones of various provirus isolates have been deciphered. See Ratner *et al.*, (1985) *Nature* 313, 277-284; Wain-Hobson *et al.*, (1985) *Cell* 40, 9-17; Sanches-Pescador *et al.*, (1985) *Science* 227, 484-492; Muesing *et al.*, (1985) *Nature* 313, 450-458. The provirus is 9734-9749 base pairs (bp) in length including two long terminal repeat (LTR) sequences. HTLV-III contains many characteristic structural features of other retroviruses: the long terminal repeats, a core protein gene (*gag*), a gene region (*pol*) encoding the virion RNA-dependent DNA polymerase and a gene encoding the virus envelope glycoproteins (*env*). Unlike other retroviruses the HTLV-III viruses contain two additional small open reading frames (SOR-I and 3'ORF) which may play a role in its unusual cytopathogenicity. See Ratner *et al.*, *supra*.

HTLV-III *gag* proteins are synthesized in the form of a polypeptide precursor of 512 amino acids which is proteolytically processed to individual *gag* proteins p17, p24 and p15. Data obtained from the analysis of nucleotide structure and the *gag* gene products of HTLV-III and ARV indicate that the p17, p24 and p15 proteins are 134, 230 and 122 amino acids long respectively. See Ratner *et al.*, Wain-Hobson *et al.*, Sanchez-Pescador *et al.*, and Muesing *et al.*, *supra*. Two precursors, p70 and p55, have been detected in HTLV-III infected cells in culture and were shown to share peptide homology with the p24 *gag* protein Roby *et al.*, (1985). Recently the p24 protein has been isolated from HTLV-III. Casey J.M., *et al.*, (1985), *J. Virol.*, 55 (2), 417-423.

Several methods for the detection of HTLV-III infection also have been developed. Solid-phase immunoassays employing inactivated HTLV-III as a whole virus antigen immunoabsorbent have been developed for the detection of antibodies against HTLV-III in sera of patients. Such assays have been shown to detect antibodies in more than 80% of sera from patients with AIDS or AIDS-related complex (ARC), or from individuals infected with HTLV-III and these are useful for diagnosing AIDS and for screening contaminated blood.

Assays employing the whole virus, however, have several drawbacks. Large quantities of the virus must be cultivated as supply for test reagents. Although rigorous safety measures can be instituted, there are dangers associated with large scale cultivation of the infectious virus. Further, there exists a risk, however small, that test reagents prepared with the inactivated virus can be contaminated with live virus. Thus, persons who handle the reagents may be subjected to the risk of HTLV-III infection.

Isolated viral p24 protein has been used in an immunoprecipitation assay for detection of anti-HTLV-III antibody in sera of AIDS patients. High serum titer of antibody was found in 730 AIDS patients. Casey, J.M., *et al.*, *supra*. Assays employing isolated viral components such as the p24 protein, however, do not eliminate the need for production of the virus. Large scale production of the virus is required for isolation of sufficient quantity of the viral protein for preparation of assay reagents.

D J Dowbenko *et al* (Proc. Nat. Acad. Sci. USA, 82, (1985) No.22, pp7748-7752) describe the use of a bacterially synthesised HTLV-III retrovirus p 24 *gag* antigen analogue having a molecular weight of 28kD, in an ELISA for detecting immune response to the AIDS retrovirus. The 28kD antigen was apparently produced by proteolytic processing of a 44kD precursor protein, arising from the expression of a p24 *gag* gene sequence in *E. coli*.

EP-A-0181150 (Chiron corporation) which is state of heart according to Article 54(3)EPC discloses an ELISA making use of *inter alia* a recombinant retroviral protein designated p41 *gag*. The p41 *gag* protein which was synthesised in *E. coli* transformed with a plasmid containing an *SphI-HpaI* fragment from the ARV-2 genome (ARV = AIDS-associated retrovirus), was stated to be a fusion protein consisting of p25 *gag* and p16 *gag* proteins.

### Disclosure of the Invention

This invention pertains to certain recombinant HTLV-III antigenic polypeptides expressed by cloned DNA segments of the *gag* region of the HTLV-III genome and to immunochemical assays for detecting antibodies

against HTLV-III core protein employing the polypeptides p92 and the polypeptide comprising the amino acid sequence as shown in Figure 5. The recombinant HTLV-III core proteins of the invention are immunoreactive with anti-HTLV-III core protein antibodies in the serum HTLV-III infected individuals. Because of this, the particular recombinant core proteins of the invention can be used to detect antibodies against HTLV-III core proteins in a biological fluid. In addition, they can be used in conjunction with immunoreactive recombinant HTLV-III envelop proteins for combined assay of antibody against HTLV-III core and envelop protein.

Three HTLV-III recombinant core antigens of the invention were expressed in bacterial cells. Restriction fragments of HTLV-III gag gene were cloned into E. coli. (Strain JA221) cells to produce three clonal cell lines. One clonal cell line, designated pG1, produces a hybrid protein containing 13 amino acid residues on the C-terminal of the 17kD virion protein, the entire p24 polypeptide and 74 amino acid residues of the amino terminal of the 15kD core ribonucleoprotein. The second clone, pG2, produces a protein similar to pG1 except that it contains no p17 sequences and lacks the NH<sub>2</sub>-terminal 77 amino acid residues of the p24. The third clone pG3 expresses a protein similar to pG2 except all but 56 amino acids of the C-terminal of p24 are absent. Thus, the antigens are chimeric molecules made up of portions of the virion p17, p24 and p15 core proteins.

The recombinant proteins are expressed by these clones as fusion proteins made up of the HTLV-III polypeptide (encoded by the cloned the gag gene segment) flanked by exogenous (vector supplied) polypeptide elements at the amino and carboxyl terminals. The fusion proteins pG1, pG2 and pG3 are strongly reactive towards anti-gag protein antibodies present in pooled sera from AIDS patients. The immunoreactivity of the pG1, pG2, and pG3 proteins indicates that strong antigenic determinants are present between amino acid residues 77 and 175 of the viral p24 protein and residues 1 and 74 of the p15 protein.

The bacterially expressed pG2 protein can be purified to virtual homogeneity. This can be accomplished by dissolution of the protein in a buffer containing a strong denaturant (8M Urea) and by subsequent dialysis and repetitive gel filtration chromatography in the presence of the denaturant. The pG2 protein purified by this technique is immunoreactive with antibody in AIDS patient sera. In strip assays, detection of anti-p24 antibody by pG2 protein correlates with detection of the antibody with whole virus.

The recombinant core antigens provide immunochemical methods for detection of antibody against HTLV-III core proteins. Immunochemical assays for detection of antibody against HTLV-III core protein can take several forms, including immunometric assays and antigen sandwich assays. The preferred type of assay is a solid phase immunometric (double antibody) assay. The purified gag derived polypeptide is immobilized by attaching it to solid phase to form an antigen immunoabsorbent.

The immunoabsorbent is used to adsorb anti-HTLV-III core protein antibody in a sample of the biological fluid. The adsorbed anti-HTLV-III antibody is detected with an anti-(human IgG) antibody which may be labeled in any conventional manner. This second antibody, directed generally against human IgG, binds to anti-HTLV-III antibody adsorbed to the immunoabsorbent and provides a detectable signal which can be evaluated as an indication of the presence of anti-HTLV-III core protein antibody in the sample.

HTLV-III core protein can be used in conjunction with HTLV-III envelop proteins (e.g. HTLV-III polypeptide 121) to enhance detection of antibody against the virus. For this purpose, the approximately equimolar amounts of the core protein (e.g. pG2) and the envelope protein can be affixed to a solid phase to form a dual antigen immunoabsorbent for use in an immunometric assay.

Expression of the pG1, pG2 and pG3 proteins in bacterial cells and demonstration of the immunoreactivity of these proteins establishes that the antigenicity of HTLV-III core proteins can be retained when the proteins are expressed in a host cell system. Further, expression of these proteins enabled identification of certain antigenic regions of p24 and p15 which can aid in rational design of additional recombinant HTLV-III core antigens. For example, other chimeric core proteins which embody these antigenic protein domains can be produced.

Immunochemical assays employing the gag derived polypeptides for detection of anti-HTLV-III core protein antibodies provide several advantages over those based on the whole virus or on isolated viral components. Viral components produced in safe host cells eliminate the need to grow large quantities of the infectious virus for preparation of assay reagents. This alleviates the risk associated with this process. Assay reagents based upon the HTLV-III antigens rather than the whole virus will help mitigate the real or perceived risk of contracting AIDS by technicians who perform the assay. Additionally, homogeneous preparations of core protein can provide for less variability in assay performance. In whole virus preparation the level of core protein may vary and affect the sensitivity of the assay.

#### Brief Description of the Drawings

Figure 1 is a schematic representation of the construction of the HTLV-III gag gene clones

Figure 2 shows SDS-PAGE analysis of HTLV-III gag gene hybrid proteins, pG1, pG2 and pG3.

Figure 3 shows a Western blot analysis of the immunoreactivity of the pG1, pG2 and pG3 HTLV-III gag

gene clones.

Figure 4 shows SDS-PAGE analysis of purified pG2.

Figure 5 shows the predicted amino acid sequence for the pG2 protein.

Figure 6 illustrates RIA results for antibodies against purified pG2 protein in sera from AIDS/ARC patients and healthy individuals.

#### Best Mode of Carrying out the Invention

Three recombinant HTLV-III core proteins, designated pG1, pG2 and pG3 were produced by cloning and expressing three segments of DNA from the *gag* gene of HTLV-III in *E. Coli*. The *gag* gene of HTLV-III is capable of encoding a protein of 512 amino acid residues. The p17 protein spans amino acid residues 1-132, the p24 is derived from amino acid residues 133-363 and the p15 from amino acid residues 378-512. Amino acids 364-377 are not present in processed, mature viral *gag* proteins, but are present in pG1, pG2 and pG3 proteins.

The segments were obtained by restriction endonuclease digestion of HTLV-III DNA. HTLV-III DNA was excised by *Sst* I digestion from  $\lambda$ BH-10, a recombinant phage comprising a 9 kb segment of the HTLV-III genome inserted into the vector  $\lambda$ gt WES $\lambda$ B. See B.H. Haha et al., *Nature* 312, 166 (1984). The *Sst*I fragment own with the nucleotide numbers above the restriction enzyme designation in Figure 1.

The pG1, pG2 and pG3 gene constructs were made by further digestion of the *Sst* I fragment. The three constructs are illustrated schematically in Figure 1. The *Sst* I fragment from  $\lambda$ BH-10 was digested with the restriction endonucleases *Pvu* II and *Bgl* II or *Pst* I and *Bgl* II. *Pvu* II/*Bgl* II digestion yielded a 949 bp fragment (corresponding to nucleotide 692 through 1641 of the HTLV-III genome) and *Pst* I/*Bgl* II digestion gave a 677 bp fragment (nucleotides 964-1641). The fragments were inserted into a the "REV" expression vector (Repligen, Cambridge, MA) to give plasmid pG1 and pG2, respectively.

Plasmid pG3 was constructed from pG2. pG2 DNA was digested with *Pst* I and *Hind* III, end repaired and ligated, resulting in excision of the *Pst* I-*Hind* III fragment from pG2.

*E. coli* cells were transformed with the recombinant vectors. Bacterial cells containing the plasmids pG1, pG2 and pG3 expressed proteins of 41kD, 33kD and 18kD, respectively. The expressed proteins were fusion proteins containing a methionine residue plus 33 vector encoded amino acid residues at the NH<sub>2</sub> terminal of the HTLV-III polypeptide and 14 vector encoded amino acids at the COOH terminal. The fusion proteins were made in large quantities by the transformed bacterial cell lines (over 10% of total cellular protein). The expressed fusion proteins were tested for reactivity with pooled AIDS patient sera by Western blot analysis. Each protein was immunoreactive.

The immunoreactivity of the pG1, pG2 and pG3 proteins indicate that these proteins exhibit strong HTLV-III antigenic determinants. The determinants are present between amino acid residues 77-175 of p24 protein and residues 1-74 of the p15 proteins.

The pG2 protein was purified to greater than 98% homogeneity by the following procedure. Soluble cellular protein was removed from pG2 cell lysates by extraction with a nondenaturant buffer. The fusion protein pG2 was contained in the insoluble cell pellet at approximately 20% purity. The pG2 protein was solubilized by suspending the cell pellet in an extraction buffer comprising 50 mM Tris-HCl, 8 M Urea, 1M NaCl, 10mM DL dithiothreitol (DTT) and 0.05% EDTA disodium salt. The suspension was homogenized and centrifuged. pG2 in the supernatant was purified by gel filtration chromatography in the extraction buffer, subsequent dialysis against distilled water, and further gel filtration chromatography in the extraction buffer. The major peak eluted from final gel filtration column contained the pG2 protein at greater than 98% purity as judged by SDS-PAGE.

Purified pG2 protein was used in a strip immunoassay to characterize sera from healthy individuals in the high risk population and sera from patients with AIDS or ARC. pG2 protein adsorbed on to nitrocellulose strips was incubated with human serum to be tested, washed, then contacted with labeled anti-human IgG to detect antibody bound to the strip. The assay was also performed with disrupted whole virus. pG2 was equally as effective as the whole virus in detecting anti-core protein antibody in sera (100% correlation). Of seropositive healthy homosexuals tested (i.e. those showing antibody reactive with the whole virus), 81% had antibodies reactive with pG2; the percentage dropped to 56% for AIDS and ARC patients.

The pG1, pG2 and pG3 proteins are hybrid proteins containing parts of naturally occurring HTLV-III antigens (i.e. the viral p17, p24 and p15 core proteins). The success achieved in expression of the immunoreactive chimeric core proteins pG1, pG2 and pG3 indicate that the p17, p24 and p15 proteins themselves can be expressed in host cell systems. In addition, other chimeric HTLV-III core proteins, especially proteins which encompass the identified antigenic domains of the virion proteins p24 and p15 can be produced. Further, the DNA segments encoding these polypeptides may be modified (e.g., by deletion, insertion or substitution of nucleotides) to design other HTLV-III core polypeptides.

Recombinant HTLV-III core proteins, including the pG1, pG2 and pG3 polypeptides, or equivalent type

polypeptides can be produced *de novo* by recombinant DNA techniques. HTLV-III now can be routinely and reproducibly isolated from patients with AIDS and propagated in a line of permissive T cells developed for this purpose. M. Popovic *et al.* *Science* 224, 497 (1984); R. C. Gallo *et al.* *Science* 224, 500 (1984). From such cells HTLV-III proviral DNA can be obtained and cloned. The designated *gag* regions of the HTLV-III genome, known to encode antigenic determinants, can be excised from the proviral DNA (generally by restriction enzyme digestion), inserted into an expression vector, preferably one which can express the polypeptide at high levels, to form a recombinant expression vector containing *gag* gene sequence. Appropriate host cells transformed by the vector can provide a system for expression of the gene product.

Alternatively, *gag* DNA segments encoding antigenic regions of the core proteins can be synthesized chemically. Several techniques are available for synthesizing DNA of desired nucleotide sequences. See, e.g., Matteucci *et al.*, *J. Am. Chem. Soc.* (1981) 103:3185; Alvarado-Urbina *et al.*, *Science* (1980) 214:270. Synthesized segments of viral DNA can be adapted and inserted into an expression vector which can be used to transform vector compatible host cells and provide for expression of the gene product.

Core proteins containing the identified antigenic regions of p24 and p15 can be synthesized chemically. The predicted amino acid sequence of the pG2 protein, for example, is shown in Figure 5; the protein, or proteins, thereof, can be synthesized by the solid phase procedure of Merrifield.

When expressed as heterologous protein in a host cell system, any of several purification techniques, in addition to the techniques described herein for purification of pG2, can be used to purify the recombinant core proteins. For use in immunoassays, the protein must be purified to substantial immunological purity. Importantly, the preparation should be free of host cell contaminants which might be reactive with antibody in human sera. Such contaminants could yield a high level of false positive results which would detract from the accuracy of the assay.

Immunochemical assays employing the polypeptides can take a variety of forms. The preferred type is a solid phase immunometric assay. In assays of this type, the purified recombinant polypeptide is immobilized on a solid phase to form an antigen-immunoabsorbent. The immunoabsorbent is incubated with the sample to be tested. The duration and conditions of the incubation are standard, those appropriate for the formation of the antigen-antibody complex. The immunoabsorbent is then separated from the sample and a labeled anti-(human IgG) antibody is used to detect human anti-HTLV-III antibody bound to the immunoabsorbent. The amount of label associated with the immunoabsorbent is compared to positive and negative controls to assess the presence or absence of anti-HTLV-III antibody.

The immunoabsorbent can be prepared by adsorbing or coupling purified polypeptide to a solid phase. Various solid phases can be used, such as beads formed of glass, polystyrene, polypropylene, dextran or other material. Other suitable solid phases include tubes or plates formed from or coated with these materials.

The recombinant core proteins can be either covalently or non-covalently bound to the solid phase by techniques such as covalent bonding via an amide or ester linkage or adsorption. After the HTLV-III polypeptide is affixed to the solid phase, the solid phase can be post-coated with an animal protein, e.g., 3% fish gelatin. This provides a blocking protein which reduces nonspecific adsorption of protein to the immunoabsorbent surface.

The immunoabsorbent functions to insolubilize anti-core protein antibody in the liquid sample tested. In blood screening for anti-HTLV-III antibody, the immunoabsorbent is incubated with blood plasma or serum. Before incubation, plasma or serum is diluted with normal animal plasma or serum. The diluent plasma or serum is derived from the same animal species that is the source of the anti-(human IgG) antibody. The preferred anti-(human IgG) antibody is goat anti-(human IgG) antibody. Thus, in the preferred format, the diluent would be goat serum or plasma. The optimal dilution factor for human plasma and serum is about 10-11 fold.

The conditions of incubation, e.g. pH and temperature, and the duration of incubation are not crucial. These parameters can be optimized by routine experimentation. Generally, the incubation will be run for 1-2 hours at about 45°C in a buffer of pH 7-8.

After incubation, the immunoabsorbent and the sample are separated. Separation can be accomplished by any conventional separation technique such as sedimentation or centrifugation. The immunoabsorbent then may be washed free of sample to eliminate any interfering substances.

To assess human antibody bound to the immunoabsorbent, the immunoabsorbent is incubated with the labeled anti-(human IgG) antibody (tracer). Generally, the immunoabsorbent is incubated with a solution of the labeled anti-(human IgG) antibody, which contains a small amount (about 1%) of the serum or plasma of the animal species which serves as the source of the anti-(human IgG) antibody. Anti-(human IgG) antibody can be obtained from any animal source. However, goat anti-(human IgG) antibody is preferred. The anti-(human IgG) antibody can be an antibody against the  $F_c$  fragment of human IgG, for example, goat anti-(human IgG)  $F_c$  antibody.

The anti-(human IgG) antibody or anti-(human IgG) $F_c$  can be labeled with a radioactive material such as

<sup>125</sup>Iodine; labeled with an optical label, such as a fluorescent material; or labeled with an enzyme such as horse radish peroxidase. The anti-human antibody can also be biotinylated and labeled avidin used to detect its binding to the immunoadsorbent.

After incubation with the labeled antibody, the immunoadsorbent is separated from the solution and the label associated with the immunoadsorbent is evaluated. Depending upon the choice of label, the evaluation can be done in a variety of ways. The label may be detected by a gamma counter if the label is a radioactive gamma emitter, or by a fluorimeter, if the label is a fluorescent material. In the case of an enzyme label detection may be done colorimetrically employing a substrate for the enzyme.

The amount of label associated with the immunoadsorbent is compared with positive and negative controls in order to determine the presence of anti-HTLV-III core protein antibody. The controls are generally run concomitantly with the sample to be tested. A positive control is a sera containing antibody against HTLV-III core protein; a negative control is a serum from healthy individuals which do not contain antibody against HTLV-III core protein.

For convenience and standardization, reagents for the performance of the immunometric assay can be assembled in assay kits. A kit for screening blood, for example, can include:

- a) an immunoadsorbent e.g. a polystyrene bead coated with a recombinant HTLV-III core polypeptide of the invention;
- b) a diluent for the serum or plasma sample, e.g. normal goat serum or plasma;
- c) an anti-(human IgG) antibody e.g. goat anti-(human IgG) antibody in buffered, aqueous solution containing about 1% goat serum or plasma;
- d) a positive control i.e. serum containing antibody against polypeptide 121; and
- e) a negative control e.g. pooled sera from healthy individuals which does not contain antibody against polypeptide 121.

If the label is an enzyme, an additional element of the kit can be the substrate for the enzyme.

Another type of assay for anti-HTLV-III antibody is an antigen sandwich assay. In this assay, a labeled HTLV-III recombinant polypeptide is used in place of anti-(human IgG) antibody to detect anti-HTLV-III antibody bound to the immunoadsorbent. The assay is based in principle on the bivalency of antibody molecules. One binding site of the antibody binds the antigen affixed to the solid phase; the second is available for binding the labeled antigen. The assay procedure is essentially the same as described for the immunometric assay except that after incubation with the sample, the immunoadsorbent is incubated with a solution of labeled core polypeptide. The HTLV-III polypeptide can be labeled with e.g. a radioisotope, or an enzyme for this type of assay.

In a third format, the bacterial protein, Protein A, which binds the F<sub>c</sub> segment of an IgG molecule without interfering with the antigen-antibody interaction can be used as the labeled tracer to detect anti-HTLV-III-antibody adsorbed to the immunoadsorbent. Protein A can be readily labeled with a radioisotope, enzyme or other detectable species.

Some serum samples appear to show stronger reactivity towards HTLV-III core protein than toward HTLV-III envelop protein. This suggests that combined testing for antibody against both viral core and envelop proteins might enhance the overall sensitivity of a test for HTLV-III infection. The use of the combination of homogenous preparations of recombinant core and envelop protein, rather than the whole virus, for this purpose would eliminate false positives encountered with assays based on preparations of whole virus (which can contain host cell contaminants). This would reduce the waste of valuable blood units.

A combination assay can be used based upon homogenous polypeptide pG2 and recombinant *env* protein. A suitable HTLV-III *env* protein is HTLV-III polypeptide 121 described in United States Patent 4774175 filed March 1, 1985. A mixture of pG2 and polypeptide 121, preferably containing approximately equimolar amounts of the two antigens, can be applied to a solid phase to form a double antigen immunoadsorbent for adsorption of antibody against either antigen. The assay would be conducted in the same manner as that described for the pG2 assay above.

Immunochemical assays employing recombinant HTLV-III core proteins for detection of antibodies against HTLV-III core protein have several advantages over those employing a whole (or disrupted) virus for this purpose. For one, assays based upon the polypeptide will alleviate the concern over growing large quantities of infectious virus and the inherent variability associated with cell culturing and virus production. Efficient expression of viral antigens in *E. coli* as other host cell systems provide a safe means of large scale production of assay reagents. Further, the assay will help mitigate the real or perceived fear of contracting AIDS by technicians in hospitals, clinics and blood banks who perform the test. As mentioned, reagents for assays based upon the whole virus (e.g. whole virus antigen immunoadsorbent), even though they are made with a disrupted, inactivated virus, present a risk of contamination with live virus. For example, a possible source of live virus contamination may be residual cell debris from the virus isolation process. Although extensive precautions can be taken to reduce the risk of contamination, it is virtually impossible to completely eliminate it. Significantly, the

risk, though minimal, may be perceived as greater than it actually is by persons who handle the test reagents. Assay reagents without whole virus can help minimize this perception of risk. Immunoassays, based upon viral components in safe host cell systems provide a substitute for assays based on the whole virus which are at least comparable in sensitivity and specificity and superior in reproducibility.

- 5 Assays employing natural, isolated HTLV-III core proteins, e.g. p24 protein, while they eliminate the use of whole virus from assay reagents, still require the growth of the virus on a large scale for a supply of the natural protein and thus do not eliminate the risks attendant to this procedure.

The invention is illustrated further by the following examples.

## 10 Example

### Bacterial strains and plasmids

- 15 E. coli strain JA221 (1pp<sup>-</sup>) was used in all experiments as the host cell. Ghayeb *et al.* (1984) EMBO J. 3. 2437-2442. Cells were grown in L-Broth supplemented with ampicillin (100 g/ml). The REV (Repligen, Cambridge, MA) expression vector was used for cloning of the HTLV-III DNA.

### DNA manipulations

- 20 Isolation of plasmid DNA and various manipulations were carried out as previously described by L.C. Ghayeb *et al.*, i.e. *supra*. Restriction enzymes were obtained from New England Biolabs. T4 DNA ligase was purchased from Boehringer Mannheim Biochemicals. The DNAs were digested with restriction enzymes in conditions described by the manufacturer.

### 25 Expression and analysis of the gag gene clones

- HTLV-III gag proteins produced by recombinant clones PG1, PG2 and PG3 were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) as described previously. See Chang, N. To *et al.*, (1985), *Science* 228, 93-96. Cells were grown in 1 ml L-broth at 37°C overnight and the cells were harvested by centrifugation at 5000 x g for 10 minutes. The cell pellets were dissolved in 200 ul of loading buffer and 20 ul was applied to a 12% SDS-polyacrylamide gel and electrophoresed under reducing conditions. Unlabeled molecular weight markers were obtained from Biorad Laboratories. [<sup>14</sup>C]-labeled molecular weight markers were obtained from Amersham. The expression of HTLV-III specific protein by the recombinant clones was detected by Western blotting analysis using sera from AIDS patients. Bacterial proteins were separated on a 12% SDS-polyacrylamide gel and transferred to nitrocellulose and blotted as described below. The blot was incubated overnight at 4°C with sera from AIDS patients or from healthy individuals. After washing, virus specific protein bands were visualized by incubation with [<sup>125</sup>I]-labeled goat antihuman IgG (see below). The blots were air dried and exposed to Kodak™ X-AR5 at -70°C with intensifying screens.

### 40 Purification of the pG2 protein

- For large scale growth, 20 ml of an overnight culture of pG2 were inoculated into 1 liter of L-Broth containing 100 µg/ml of ampicillin and 0.025% antifoam, and shaken at 37°C. The cells were harvested after 8 hr and washed with 50 mM Tris-HCl pH 8.5 (sonication buffer). 25 g of cell pellet were suspended in 70 ml of sonication buffer and sonicated in two portions at 70 W for eight 30 sec bursts with a 60 sec cooling period between each burst. The lysed cells were then centrifuged at 10,000 xg for 30 min. All of the pG2 protein was found in the pellet and constituted approximately 20% of the total protein as judged by SDS-PAGE.

- The pellet containing the pG2 protein was suspended in 50 mM Tris-HCl pH 8.5 containing 8 M Urea, 1 M NaCl, 10 mM DL dithiothreitol (DTT) and 0.05% EDTA disodium salt (extraction buffer). The suspension was incubated at 45°C for 60 min and centrifuged at 10,000 xg for 30 min. The resulting supernatant was applied to a Sephacryl™S-300 gel filtration column (5 x 80 cm) previously equilibrated with extraction buffer containing 5 mM DTT. The column was eluted in the same buffer at a flow rate of 0.5 ml/min at room temperature and the fractions (10 ml) were monitored by U.V. absorption at 280 nm. The pG2 protein, found in the second main peak, was pooled and dialyzed exhaustively against distilled water at 4°C. During dialysis the pG2 protein was precipitated quantitatively. The precipitated protein was then redissolved in 10 ml of extraction buffer containing 10 mM DTT and incubated at 45°C for 30 min. The resulting solution was applied to a second Sephacryl™S-300 column (2.6 x 65 cm) under identical conditions to the first column. The major peak contained the pG2 protein which was 95% pure as judged by SDS-PAGE. The protein was further purified by repeating the second column

purification under identical conditions. The main peak from the third S-300 column contained the pG2 protein in 98% purity. The yield was 50 mg and this preparation was used for screening human sera (see below).

#### Immunoreactivity of pG2 with Human Sera

5

50µg of pure pG2 protein or 430µg of purified disrupted HTLV-III virus, were electrophoresed on a 12% SDS polyacrylamide gel (13 cm x 13 cm x 1.5 mm) and transferred to nitrocellulose using a Biorad Trans-Blot® apparatus. The electroblotting buffer used was 20% aqueous methanol containing 0.016 M Tris base and 0.13 M glycine, and transfer was performed at 40 volts at 4°C overnight. The nitrocellulose paper was then shaken for 2 hr at 37°C with 60 ml of PBS containing 5% non-fat dry milk, 0.1% sodium azide and 0.1% antifoam (milk buffer) and then for 2 hrs at room temperature with 60 ml of 5% normal goat serum in milk buffer. At this stage, the blocked nitrocellulose was either stored at -20°C, or used directly for the strip assay. The nitrocellulose was cut into 13 cm x 0.5 cm strips, and each strip was rocked overnight at 4°C with 4 mL of milk buffer containing 5% normal goat serum and 40µl of the human serum to be tested in a 15 ml disposable conical tube. The next day the milk solution was replaced with 10 ml of 0.15% sodium deoxycholate, 0.1M NaCl, 0.5% Triton X-100™, 0.1 mM phenylmethylsulfonyl fluoride in 10 mM sodium phosphate pH 7.5 (wash buffer) and the tubes were rocked for 1 hr. The wash buffer was removed and replaced with 4ml 5% goat serum in milk buffer and the tubes were rocked for 1 hr, at which time <sup>125</sup>I-labeled goat anti-human IgG (10<sup>6</sup> cpm/ml) was added. After 30 min, the strips were washed for 1 hr with 10 ml of wash buffer, air dried and exposed to Kodak™ XAR-5 film at -70°C with intensifying screens.

20

#### Radioimmunoassay

96 well microtiter dishes were coated with the antigen at 100µg/ml in 50 % Tris-HCl pH 8.0. After an overnight incubation, the wells were washed three times with phosphate buffered saline (PBS). The wells were then post coated with 200 µl 3% fish gelatin (Norland Products, Inc.) in PBS containing 0.1% sodium azide. The fish gelatin solution was removed and each well was filled with 200 µl of 1:5 or 1:10 dilutions of the test serum in PBS containing 10% normal goat serum, 10% anti-*E. coli* goat serum and 1% fish gelatin. After one hour at room temperature, the wells were washed three times with PBS and 200µl of [<sup>125</sup>I]-labeled goat anti-human IgG (Fc portion) in 1% normal goat serum, 1% fish gelatin in PBS at 1.5x10<sup>6</sup> cpm/ml was added to each well. After one hour at room temperature, the plates were washed four times with PBS and once with distilled water and counted.

30

## RESULTS

35

#### Construction of the HTLV-III gag gene clones

The isolation of recombinant phage clone BH10 containing the unintegrated linear form of HTLV-III proviral DNA has been reported previously. Shaw et al., (1985), *Science*, 226, 1165-1171. The 9 Kb HTLV-III insert of phage BH10 was released by *Sst*I cleavage within the R element of the LTR (See Figure 1). The *Sst*I fragment was then digested with either *Pvu*II and *Bgl*II or *Pst*I and *Bgl*II. The 949 bp *Pvu*II-*Bgl*II fragment and the 677 bp *Pst*I-*Bgl*II fragments were inserted into the REV expression vector (Repligen, Cambridge, MA) to give pG1 and pG2 respectively (Figure 1). Clone pG3 was constructed from pG2. pG2 DNA was digested with *Pst*I and *Hind*III, end repaired and ligated. Thus, in pG3 the *Pst*I-*Hind*III fragment was deleted from the HTLV-III DNA insert of pG2. As seen from Figure 1, the three constructs carry HTLV-III DNA that is predicted to code for chimeric peptides containing various portions of the p17, p24 and p15 viral gag proteins. See Ratner et al., (1985), *Nature*, 313, 277-284. The sizes of the expressed proteins are larger than predicted since the expression vector supplies the initiation methionine codon plus 35 amino residues at the NH<sub>2</sub>-terminus of each expressed protein.

45

50

#### Expression of the HTLV-III gag gene clones

*E. coli* transformed with plasmids, pG1, pG2 or pG3 were found to produce proteins of 41kD, 33kD and 18kD, respectively, as demonstrated by SDS-polyacrylamide gel electrophoresis of total bacterial cell lysates. SDS-PAGE analysis of HTLV-III gag gene proteins is shown in Figure 2. Cells from 1ml cultures were centrifuged and the pellets resuspended in 200µl of SDS sample buffer and analyzed by SDS-PAGE as described above. 20 µl of cell lysate were loaded per lane and gels were stained with Coomassie brilliant blue R250. (Lane 1, molecular weight markers, lane 2, control cells with no plasmid, lane 3, pG1, lane 4, pG2, lane 5, pG3, lane

55



6, cells carrying the REV vector containing no HTLV-III DNA. The number on the left designate the molecular weights in kilodaltons.)

All three proteins were made in large quantities (over 10% of total cellular protein in these cells) but were not detected in the host cell with or without the REV vector alone. The overproduction of the plasmid encoded HTLV-III gag proteins caused a marked decrease in the rate of cell growth. The kinetics of the growth rate could be correlated with the accumulation of the gag gene products in the cytoplasm although no cell lysis was observed (data not shown). Maximum accumulation was observed at 8 hours after the start of the log phase growth period. In addition, the expressed gag gene products were present as aggregates containing membrane proteins after disruption of the cells. Depending on growth conditions, HTLV-III gag proteins of smaller size could be detected on SDS-PAGE gels (Figure 2). The products are likely due to the degradation of the major high molecular weight gag proteins with increasing growth time.

#### Immunochemical characterization of the gag gene products

The bacterial expressed HTLV-III gag-specific protein in cells carrying pG1, pG2 or pG3 were detected by Western blot analysis using sera pooled from AIDS patients. The results of this analysis are shown in Figure 3. SDS-PAGE analysis was performed exactly as in Figure 2. Transfer of proteins to nitrocellulose paper, reaction with antibodies and detection of immunoreactive bands is described above. Figure 3 shows a blot in which lane 1 is control cells, lane 2 is pG1, lane 3 is pG2 and lane 4 is pG3. The blot was treated with pooled sera from AIDS patients. The numbers on the left designate the relative position of the [<sup>14</sup>C] molecular weight markers that were run along with the samples in lanes 1-4, but are not shown in the figure. The result clearly shows the synthesis of specifically cross-reacting HTLV-III peptide in recombinant clones containing pG1, pG2 and pG3. The immunoreactive proteins in each clone corresponded to the expressed proteins, 41kD, 33kD, 18kD, seen in the Coomassie blue stained SDS-polyacrylamide gel (Figure 2). There was no HTLV-III virion-specific peptide detected in lysate of control JA221 cells.

The product of pG2 was purified to greater than 98% homogeneity as judged by SDS-PAGE. Figure 4 shows SDS-PAGE analysis of pG2 purified as described above. PG-2 protein eluted from a Sephacryl® S-300 column in 50 mM Tris-HCl pH 8.5 containing 8M Urea, 1M NaCl and 5 mM DTT, was mixed with an equal volume of 2X SDS-PAGE sample buffer, heated at 100°C for 5 min and applied to two identical 12% SDS-PAGE gels. One of the gels was stained with Coomassie Brilliant Blue (panel A), while the other transferred to nitrocellulose and the blot treated with pooled sera from AIDS patients (panel B) as in Figure 3. Panel A, lane 1 is molecular weight markers, lane 2, 3, 4 are pure pG2 at 2, 5 and 10 g respectively. Panel B is identical to A except that lane 1 was run with [<sup>14</sup>C]-labeled molecular weight markers.

The major band is of 33 kD while there is a minor band of 30 kD which is also seen in total cell lysates (Figure 2) and is most likely a degradation product. A very minor band of 65 kD can also be seen and is most likely to be the dimer form of pG2. All the bands that are visible by Coomassie blue staining are also immunoreactive towards HTLV-III specific antibodies present in sera from AIDS patients (Figure 4B) as well as the anti-P24 mouse monoclonal antibody (data not shown). We feel confident that the pG2 protein is essentially free of contaminating *E. coli* proteins.

The purified pG2 protein was used to screen for antibodies directed towards the core p24 protein in human sera, using a strip assay based on the western blot technique. The same samples were also tested under identical conditions, using the purified, disrupted HTLV-III virus. The results are summarized in Table 1.

Table 1

5	Clinical Status	No. Tested	No. Positive For p24 of HTLV-III	No. Positive Using pG2
	Healthy donors	50	0	0
	Healthy homosexuals*	49	17	17
10	ARC**	51	28	28
	AIDS**	34	19	19

15 \*Only 21 of these donors were seropositive for antibodies to either p24 and/or gp41 of HTLV-III. In addition, the same individuals who were positive for p24 antibodies using the whole virus assay were also positive for antibodies to pG2.

20 \*\*All these sera were positive for antibodies to gp41.

25 The results show that there is 100% correlation between p24 antibodies detected by pG2 protein and those detected by the whole virus. In addition, none of the normal donor controls were reactive with pG2 protein. This indicates the recombinant pG2 protein can substitute adequately for the whole virus when detection of p24 antibodies is required. The data presented in Table I also show that of the 21 seropositive healthy homosexuals tested, 17 (81%) had detectable antibodies to the p24. In both ARC and AIDS patients, the percentage drops to 56%. Whether the anti-p24 antibody titer is an indication of the progress of HTLV-III infection remains to be studied. In this regard, the uses of pG2 protein in such studies would be preferable since the levels of p24 protein in different virus preparations may vary and may affect the sensitivity of the assay.

30 Partially purified pG2 protein was tested in a solid phase RIA. Details of the plate RIA assay are given above. The pG2 protein preparation used was only "partially" purified. 24 sera from AIDS/ARC patients and 24 sera from healthy individuals were used in the assay and results were plotted on a semi-log scale. The horizontal dotted line designates the cut-off points so that values below the line are considered negative while those above are considered positive. The results are shown in Figure 6. The results indicated that 18 out of the 24 AIDS or ARC patients sera tested were reactive with the antigen. The 6 sera from patients with AIDS or ARC that were negative in the RIA assay were found to contain no detectable amounts of anti-p24 antibodies as assayed by a strip immunoassay base on Western blot technique using the purified disrupted whole virus (data not shown). Of the 24 normal human sera tested in the RIA, only one was positive but was negative when tested with the purified virus in a Western blot (data not shown). The reactivity of the one normal sample may be due to the presence of unusually high titre of anti-*E. coli* antibodies present in that particular serum and the fact that the pG2 antigen preparation contained trace amounts of *E. coli* protein impurities. This nonspecific immunoreactivity can be eliminated by absorption of this serum with Sepharos® 4B conjugated with *E. coli* extract. Alternatively, better purified pG2 preparations such as the preparation used in the strip assay can be used:

#### Claims

50 Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A method of detecting antibody against HTLV-III core protein in a biological fluid (eg. human serum or plasma) comprising the steps of:

- 55 a. providing an antigen immunoabsorbent comprising a solid phase to which is attached an HTLV-III core antigen which is a chimeric antigen comprising an amino acid sequence beginning at amino acid 1 through 99 and extending to amino acid number 228 of the sequence as shown in Figure 5, the chimeric antigen being immunoreactive with antibody against HTLV-III core protein;
- b. incubating the immunoabsorbent with a sample of the biological fluid to be tested under conditions which

allow antibody in the sample to complex with the antigen immunoabsorbent;

c. separating the immunoabsorbent from the sample; and

d. determining antibody bound to the immunoabsorbent as an indication of antibody against HTLV-III core protein in the sample.

5 2. A method of Claim 1, wherein the step of determining the antibody bound to the immunoabsorbent comprises;

a. incubating the immunoabsorbent with a labelled antibody against immunoglobulin of the species from which the biological fluid is derived (for example in the case of human serum or plasma, anti-human Ig antibody);

10 b. separating the immunoabsorbent from the labelled antibody; and

c. detecting the label associated with the immunoabsorbent as an indication of antibody against HTLV-III core protein in the sample.

3. A method according to claim 1 or claim 2 wherein the HTLV-III core protein is the pG2 polypeptide having an amino acid sequence substantially as shown in Figure 5.

15 4. A method of detecting antibody against HTLV-III core protein in human plasma or serum according to any of claims 1-3, comprising the steps of:

a. providing an antigen immunoabsorbent comprising a polystyrene bead coated with an essentially homogeneous purified preparation of pG2 polypeptide;

20 b. incubating the immunoabsorbent with a sample of human plasma or serum under conditions which permit anti-HTLV-III core protein antibody in the sample to complex with the pG2 polypeptide;

c. separating the immunoabsorbent from the sample;

d. incubating the immunoabsorbent with a solution of labelled anti-human Ig antibody;

e. separating the immunoabsorbent from the solution of labelled antibody; and

25 f. detecting the label associated with the immunoabsorbent as an indication of anti-HTLV-III core protein antibody in the sample.

5. An immunoabsorbent comprising a solid phase support having attached thereto an HTLV-III core protein which is a chimeric antigen as defined in any one of the preceding claims.

6. An assay for antibody against HTLV-III in a biological fluid comprising the steps of:

30 a. providing an immunoabsorbent comprising a solid phase to which is attached a mixture of a recombinant HTLV-III core protein as defined in any one of the preceding Claims, said core protein being immunoreactive with antibody against HTLV-III core proteins; and recombinant HTLV-III envelop protein immunoreactive with antibody against HTLV-III envelop protein;

b. incubating the immunoabsorbent with a sample of biological fluid;

c. separating the immunoabsorbent from the sample; and

35 d. determining antibody bound to the immunoabsorbent as an indication of antibody against HTLV-III in the sample.

7. An assay for antibody against HTLV-III in a biological fluid according to claim 6, comprising the steps of:

40 a. providing an immunoabsorbent comprising a solid phase to which is attached approximately an equal amount of pG2 polypeptide and HTLV-III polypeptide 121;

b. incubating the immunoabsorbent with a sample of biological fluid;

c. separating the immunoabsorbent from the sample;

d. incubating the immunoabsorbent with a solution of anti-human Ig antibody;

e. separating the immunoabsorbent from the sample; and

45 f. detecting the label associated with the immunoabsorbent as an indication of anti-HTLV-III antibody in the sample.

8. An immunoabsorbent as defined in claim 7, said immunoabsorbent comprising a solid phase coated with an equal amount of pG2 polypeptide and polypeptide 121.

50 9. A recombinant HTLV-III core antigen immunoreactive with antibody against HTLV-III core protein, said core antigen being as defined in claim 1 and being useful in the method of claim 1.

10. pG2 polypeptide, said polypeptide being useful in the method of any one of claims 1 to 4 or the assay of claim 6 or claim 7.

11. An essentially homogeneous preparation of pG2 protein, said preparation being useful in the method of any one of claims 1 to 4 or the assay of claim 6 or claim 7.

55

Claims for the following Contracting State : AT

1. A method of detecting antibody against HTLV-III core protein in a biological fluid (eg. human serum)

plasma) comprising the steps of:

- a. providing an antigen immunoabsorbent comprising a solid phase to which is attached an HTLV-III core antigen which is a chimeric antigen comprising an amino acid sequence beginning at amino acid I through 99 and extending to amino acid number 228 of the sequence as shown in Figure 5, the chimeric antigen being immunoreactive with antibody against HTLV-III core protein;
- b. incubating the immunoabsorbent with a sample of the biological fluid to be tested under conditions which allow antibody in the sample to complex with the antigen immunoabsorbent;
- c. separating the immunoabsorbent from the sample; and
- d. determining antibody bound to the immunoabsorbent as an indication of antibody against HTLV-III core protein in the sample.

2. A method of Claim 1, wherein the step of determining the antibody-bound to the immunoabsorbent comprises;

- a. incubating the immunoabsorbent with a labelled antibody against immunoglobulin of the species from which the biological fluid is derived (for example in the case of human serum or plasma, anti-human Ig antibody);
- b. separating the immunoabsorbent from the labelled antibody; and
- c. detecting the label associated with the immunoabsorbent as an indication of antibody against HTLV-III core protein in the sample.

3. A method according to claim 1 or claim 2 wherein the HTLV-III core protein is the pG2 polypeptide having an amino acid sequence substantially as shown in Figure 5.

4. A method of detecting antibody against HTLV-III core protein in human plasma or serum according to any of claims 1-3, comprising the steps of:

- a. providing an antigen immunoabsorbent comprising a polystyrene bead coated with an essentially homogeneous purified preparation of pG2 polypeptide;
- b. incubating the immunoabsorbent with a sample of human plasma or serum under conditions which permit anti-HTLV-III core protein antibody in the sample to complex with the pG2 polypeptide;
- c. separating the immunoabsorbent from the sample;
- d. incubating the immunoabsorbent with a solution of labelled anti-human Ig antibody;
- e. separating the immunoabsorbent from the solution of labelled antibody; and
- f. detecting the label associated with the immunoabsorbent as an indication of anti-HTLV-III core protein antibody in the sample.

5. A method of making an immunoabsorbent comprising attaching to a solid phase support an HTLV-III core protein which is a chimeric antigen as defined in any one of the preceding claims.

6. An assay for antibody against HTLV-III in a biological fluid comprising the steps of:

- a. providing an immunoabsorbent comprising a solid phase to which is attached a mixture of a recombinant HTLV-III core protein as defined in any one of the preceding claims, said core protein being immunoreactive with antibody against HTLV-III core proteins; and recombinant HTLV-III envelop protein immunoreactive with antibody against HTLV-III envelop protein;
- b. incubating the immunoabsorbent with a sample of biological fluid;
- c. separating the immunoabsorbent from the sample; and
- d. determining antibody bound to the immunoabsorbent as an indication of antibody against HTLV-III in the sample.

7. An assay for antibody against HTLV-III in a biological fluid according to claim 6, comprising the steps of:

- a. providing an immunoabsorbent comprising a solid phase to which is attached approximately an equal amount of pG2 polypeptide and HTLV-III polypeptide 121;
- b. incubating the immunoabsorbent with a sample of biological fluid;
- c. separating the immunoabsorbent from the sample;
- d. incubating the immunoabsorbent with a solution of anti-human Ig antibody;
- e. separating the immunoabsorbent from the sample; and
- f. detecting the label associated with the immunoabsorbent as an indication of anti-HTLV-III antibody in the sample.

8. An immunoabsorbent as defined in claim 7, said immunoabsorbent comprising a solid phase coated with an equal amount of pG2 polypeptide and polypeptide 121.

# Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

- 5 1. Verfahren zum Nachweis eines Antikörpers gegen HTLV-III-Kernprotein in einem biologischen Fluid (z.B. Humanserum oder Plasma), bestehend aus den Schritten, daß
  - a. ein Antigen-Immunoabsorbens mit einer festen Phase bereitgestellt wird, an dem ein HTLV-III-Kernantigen angeheftet ist, welches ein Schimärenantigen ist, mit einer Aminosäuresequenz, beginnend bei Aminosäure 1 bis 99 und sich erstreckend bis Aminosäure Nr. 228 der Sequenz wie in Fig. 5 gezeigt, wobei
  - 10 das Schimärenantigen immunoreaktionsfähig mit einem Antikörper gegen HTLV-III-Kernprotein ist,
  - b. das Immunoabsorbens mit einer Probe des zu untersuchenden biologischen Fluids unter Bedingungen inkubiert wird, die es dem Antikörper in der Probe erlauben, einen Komplex mit dem Antigen-Immunoabsorbens zu bilden,
  - c. das Immunoabsorbens von der Probe getrennt wird und
  - 15 d. der an das Immunoabsorbens gebundene Antikörper als eine Anzeige von Antikörpern gegen HTLV-III-Kernprotein in der Probe bestimmt wird.
2. Verfahren nach Anspruch 1, bei dem der Schritt der Bestimmung des an das Immunoabsorbens gebundenen Antikörpers darin besteht, daß
  - a. das Immunoabsorbens mit einem markierten Antikörper gegen Immunglobulin der Spezies inkubiert
  - 20 wird, von der das biologische Fluid abgeleitet ist (zum Beispiel im Falle von Humanserum oder Plasma Anti-Human-Ig-Antikörper),
  - b. das Immunoabsorbens von dem markierten Antikörper getrennt wird, und
  - c. die mit dem Immunoabsorbens assoziierte Markierung als eine Anzeige von Antikörpern gegen HTLV-III-Kernprotein in der Probe nachgewiesen wird.
- 25 3. Verfahren nach Anspruch 1 oder Anspruch 2, bei dem das HTLV-III-Kernprotein das pG2-Polypeptid ist mit einer Aminosäuresequenz im wesentlichen wie in Fig. 5 gezeigt.
4. Verfahren zum Nachweis eines Antikörpers gegen HTLV-III-Kernprotein in Humanplasma oder Serum nach einem der Ansprüche 1 bis 3, mit den Schritten, daß
  - a. ein Antigen-Immunoabsorbens bereitgestellt wird, das eine mit einer im wesentlichen homogenen gereinigten Zubereitung des pG2-Polypeptids überzogene Polystyrolperle umfaßt,
  - 30 b. das Immunoabsorbens mit einer Probe von Humanplasma oder serum unter Bedingungen inkubiert wird, die es dem Anti-HTLV-III-Kernprotein-Antikörper in der Probe erlauben, mit dem pG2-Polypeptid einen Komplex zu bilden,
  - c. das Immunoabsorbens von der Probe getrennt wird,
  - 35 d. das Immunoabsorbens mit einer Lösung eines markierten Anti-Human-Ig-Antikörpers inkubiert wird,
  - e. das Immunoabsorbens von der Lösung des markierten Antikörpers getrennt wird und
  - f. die mit dem Immunoabsorbens assoziierte Markierung als eine Anzeige von Anti-HTLV-III-Kernprotein-Antikörpern in der Probe nachgewiesen wird.
5. Immunoabsorbens, bestehend aus einem Festphasenträger mit einem daran angehefteten HTLV-III-Kernprotein, das ein Schimärenantigen nach einem der vorhergehenden Ansprüche ist.
- 40 6. Untersuchung auf Antikörper gegen HTLV-III in einem biologischen Fluid, bestehend aus den Schritten, daß
  - a. ein eine feste Phase umfassendes Immunoabsorbens bereitgestellt wird, an dem ein Gemisch aus einem rekombinanten HTLV-III-Kernprotein nach einem der vorhergehenden Ansprüche, wobei das Kernprotein
  - 45 immunoreaktionsfähig mit Antikörpern gegen HTLV-III-Kernproteinen ist, und rekombinantem HTLV-III-Hüllprotein, das immunoreaktionsfähig mit Antikörpern gegen HTLV-III-Hüllprotein ist, angeheftet ist,
  - b. das Immunoabsorbens mit einer Probe von biologischem Fluid inkubiert wird,
  - c. das Immunoabsorbens von der Probe getrennt wird und
  - d. an das Immunoabsorbens gebundene Antikörper als eine Anzeige von Antikörpern gegen HTLV-III in der Probe bestimmt werden.
  - 50 7. Untersuchung auf Antikörper gegen HTLV-III in einem biologischen Fluid nach Anspruch 6, bestehend aus den Schritten, daß
    - a. ein eine feste Phase umfassendes Immunoabsorbens bereitgestellt wird, an das in etwa eine gleiche Menge von pG2-Polypeptid und HTLV-III-Polypeptid 121 angeheftet ist,
    - 55 b. das Immunoabsorbens mit einer Probe von biologischem Fluid inkubiert wird,
    - c. das Immunoabsorbens von der Probe getrennt wird,
    - d. das Immunoabsorbens mit einer Lösung von Anti-human-Ig-Antikörpern inkubiert wird,
    - e. das Immunoabsorbens von der Probe getrennt wird und

f. die mit dem Immunoabsorbens assoziierte Markierung als eine Anzeige von Anti-HTLV-III-Antikörpern in der Probe nachgewiesen wird.

8. Immunoabsorbens nach Anspruch 7, wobei das Immunoabsorbens eine mit einer gleichen Menge von pG2-Polypeptid und Polypeptid 121 überzogene feste Phase umfaßt.

5 9. Rekombinantes HTLV-III-Kernantigen, immunoreaktionsfähig mit einem Antikörper gegen HTLV-III-Kernprotein, wobei das Kernantigen entsprechend der Definition in Anspruch 1 ist und in dem Verfahren nach Anspruch 1 verwendbar ist.

10. pG2-Polypeptid, wobei das Polypeptid in dem Verfahren nach einem der Ansprüche 1 bis 4 oder der Untersuchung nach Anspruch 6 oder Anspruch 7 verwendbar ist.

10 11. Im wesentlichen homogene Zubereitung von pG2-Protein, wobei die Zubereitung in dem Verfahren nach einem der Ansprüche 1 bis 4 oder der Untersuchung nach Anspruch 6 oder Anspruch 7 verwendbar ist.

#### Patentansprüche für folgenden Vertragsstaat : AT

15 1. Verfahren zum Nachweis eines Antikörpers gegen HTLV-III-Kernprotein in einem biologischen Fluid (z.B. Humanserum oder Plasma), bestehend aus den Schritten, daß

a. ein Antigen-Immunoabsorbens mit einer festen Phase bereitgestellt wird, an dem ein HTLV-III-Kernantigen angeheftet ist, welches ein Schimärenantigen ist, mit einer Aminosäuresequenz, beginnend bei Aminosäure 1 bis 99 und sich erstreckend bis Aminosäure Nr. 228 der Sequenz wie in Fig. 5 gezeigt, wobei

20 das schimärenantigen immunoreaktionsfähig mit einem Antikörper gegen HTLV-III-Kernprotein ist, b. das Immunoabsorbens mit einer Probe des zu untersuchenden biologischen Fluids unter Bedingungen inkubiert wird, die es dem Antikörper in der Probe erlauben, einen Komplex mit dem Antigen-Immunoabsorbens zu bilden,

c. das Immunoabsorbens von der Probe getrennt wird und

25 d. der an das Immunoabsorbens gebundene Antikörper als eine Anzeige von Antikörpern gegen HTLV-III-Kernprotein in der Probe bestimmt wird.

2. Verfahren nach Anspruch 1, bei dem der Schritt der Bestimmung des an das Immunoabsorbens gebundenen Antikörpers darin besteht, daß

a. das Immunoabsorbens mit einem markierten Antikörper gegen Immunglobulin der Spezies inkubiert wird, von der das biologische Fluid abgeleitet ist (zum Beispiel im Falle von Humanserum oder Plasma Anti-Human-Ig-Antikörper),

30 b. das Immunoabsorbens von dem markierten Antikörper getrennt wird, und

c. die mit dem Immunoabsorbens assoziierte Markierung als eine Anzeige von Antikörpern gegen HTLV-III-Kernprotein in der Probe nachgewiesen wird.

35 3. Verfahren nach Anspruch 1 oder Anspruch 2, bei dem das HTLV-III-Kernprotein das pG2-Polypeptid ist mit einer Aminosäuresequenz im wesentlichen wie in Fig. 5 gezeigt.

4. Verfahren zum Nachweis eines Antikörpers gegen HTLV-III-Kernprotein in Humanplasma oder Serum nach einem der Ansprüche 1 bis 3, mit den Schritten, daß

a. ein Antigen-Immunoabsorbens bereitgestellt wird, das eine mit einer im wesentlichen homogenen gereinigten Zubereitung des pG2-Polypeptids überzogene Polystyrolperle umfaßt,

40 b. das Immunoabsorbens mit einer Probe von Humanplasma oder Serum unter Bedingungen inkubiert wird, die es dem Anti-HTLV-III-Kernprotein-Antikörper in der Probe erlauben, mit dem pG2-Polypeptid einen Komplex zu bilden,

c. das Immunoabsorbens von der Probe getrennt wird,

45 d. das Immunoabsorbens mit einer Lösung eines markierten Anti-Human-Ig-Antikörpers inkubiert wird,

e. das Immunoabsorbens von der Lösung des markierten Antikörpers getrennt wird und

f. die mit dem Immunoabsorbens assoziierte Markierung als eine Anzeige von Anti-HTLV-III-Kernprotein-Antikörpern in der Probe nachgewiesen wird.

50 5. Verfahren zur Herstellung eines Immunoabsorbens, bestehend aus dem Anheften eines HTLV-III-Kernproteins, das ein Schimärenantigen nach einem der vorhergehenden Ansprüche ist, an einen Festphasenträger.

6. Untersuchung auf Antikörper gegen HTLV-III in einem biologischen Fluid, bestehend aus den Schritten, daß

a. ein eine feste Phase umfassendes Immunoabsorbens bereitgestellt wird, an dem ein Gemisch aus einem rekombinanten HTLV-III-Kernprotein nach einem der vorhergehenden Ansprüche, wobei das Kernprotein immunoreaktionsfähig mit Antikörpern gegen HTLV-III-Kernproteinen ist, und rekombinantes HTLV-III-Hüllprotein, das immunoreaktionsfähig mit Antikörpern gegen HTLV-III-Hüllprotein ist, angeheftet ist,

55 b. das Immunoabsorbens mit einer Probe von biologischem Fluid inkubiert wird,

- c. das Immunoabsorbens von der Probe getrennt wird und
- d. an das Immunoabsorbens gebundene Antikörper als eine Anzeige von Antikörpern gegen HTLV-III in der Probe bestimmt werden.
- 7. Untersuchung auf Antikörper gegen HTLV-III in einem biologischen Fluid nach Anspruch 6, bestehend aus den Schritten, daß
  - a. ein eine feste Phase umfassendes Immunoabsorbens bereitgestellt wird, an das in etwa eine gleiche Menge von pG2-Polypeptid und HTLV-III-Polypeptid 121 angeheftet ist,
  - b. das Immunoabsorbens mit einer Probe von bio-logischem Fluid inkubiert wird,
  - c. das Immunoabsorbens von der Probe getrennt wird,
  - 10 d. das Immunoabsorbens mit einer Lösung von Anti-human-Ig-Antikörpern inkubiert wird,
  - e. das Immunoabsorbens von der Probe getrennt wird und
  - f. die mit dem Immunoabsorbens assoziierte Markierung als eine Anzeige von Anti-HTLV-III-Antikörpern in der Probe nachgewiesen wird.
- 8. Immunoabsorbens nach Anspruch 7, wobei das Immunoabsorbens eine mit einer gleichen Menge von pG2-Polypeptid und Polypeptid 121 überzogene feste Phase umfaßt.

### Revendications

20 **Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Procédé de détection d'anticorps contre les protéines de noyau d'HTLV-III dans un fluide biologique (tel que le plasma ou le sérum humain) comprenant les étapes suivantes :
  - 25 a. alimenter en un immunoabsorbant d'antigène comprenant une phase solide sur laquelle est fixée un antigène de noyau d'HTLV-III qui est un antigène chimérique comprenant une séquence aminoacide commençant de l'acide aminé 1 au 99 et s'étendant jusqu'au numéro 228 de la séquence aminoacide, de la forme représentée à la figure 5, l'antigène chimérique étant immunoréactif par rapport à l'anticorps contre les protéines de noyau d'HTLV-III;
  - 30 b. incubier l'immunoabsorbant avec un échantillon du fluide biologique à tester, dans des conditions permettant à l'anticorps dans l'échantillon de se complexer avec l'immunoabsorbant d'antigène;
  - c. séparer l'immunoabsorbant de l'échantillon; et
  - d. déterminer la fixation de l'anticorps sur l'immunoabsorbant, en tant qu'indication de l'anticorps contre les protéines de noyau d'HTLV-III dans l'échantillon.
- 35 2. Procédé selon la revendication 1, dans lequel l'étape de détermination de la fixation de l'anticorps sur l'immunoabsorbant comprend elle-même les étapes suivantes :
  - a. incubier l'immunoabsorbant avec un anticorps marqué, contre l'immunoglobuline de l'espèce dont dérive le fluide biologique (tel l'anticorps anti-Ig humaine dans le cas du plasma ou du sérum humain);
  - b. séparer l'immunoabsorbant de l'anticorps marqué;
  - 40 c. détecter le marqueur associé à l'immunoabsorbant en tant qu'indication de l'anticorps contre les protéines de noyau d'HTLV-III dans l'échantillon.
3. Procédé selon l'une des revendications 1 ou 2 dans lequel les protéines de noyau d'HTLV-III sont le polypeptide pG2 présentant une séquence aminoacide essentiellement de la forme représentée à la figure 5.
4. Procédé de détection d'anticorps contre les protéines de noyau d'HTLV-III dans le sérum ou le plasma humain selon l'une quelconque des revendications 1 à 3 comprenant les étapes suivantes :
  - 45 a. alimenter en un immunoabsorbant d'antigène comprenant une granule de polystyrène enduite d'une préparation purifiée pratiquement homogène de polypeptide pG2;
  - b. incubier l'immunoabsorbant avec un échantillon de sérum ou de plasma humain dans des conditions qui permettent à l'anticorps contre les protéines de noyau d'HTLV-III dans l'échantillon, de se complexer avec le polypeptide pG2;
  - 50 c. séparer l'immunoabsorbant de l'échantillon;
  - d. incubier l'immunoabsorbant avec une solution d'anticorps marqué anti-Ig humaine;
  - e. séparer l'immunoabsorbant de la solution d'anticorps marqué; et
  - f. détecter le marqueur associé à l'immunoabsorbant en tant qu'indication de l'anticorps contre les protéines de noyau d'HTLV-III dans l'échantillon.
- 55 5. Immunoabsorbant comprenant une phase solide de support à laquelle sont liées des protéines de noyau d'HTLV-III qui sont un antigène chimérique tel que défini dans l'une quelconque des revendications précédentes.

6. Test pour anticorps contre l'HTLV-III dans un fluide biologique comprenant les étapes suivantes :

- a. alimenter en un immunoadsorbant comprenant une phase solide sur laquelle est fixé un mélange de protéines de noyau d'HTLV-III recombinées telles que définies dans l'une quelconque des revendications précédentes, lesdites protéines de noyau étant immunoréactives avec l'anticorps contre les protéines de noyau d'HTLV-III, mélange comprenant également des protéines d'enveloppe d'HTLV-III recombinantes immunoréactives avec un anticorps contre les protéines d'enveloppe d'HTLV-III;
- b. incubier l'immunoadsorbant avec un échantillon de fluide biologique;
- c. séparer l'immunoadsorbant de l'échantillon; et
- d. déterminer la fixation de l'anticorps sur l'immunoadsorbant en tant qu'indication de l'anticorps contre l'HTLV-III dans l'échantillon.

7. Test pour les anticorps contre l'HTLV-III dans un fluide biologique selon la revendication 6 comprenant les étapes suivantes :

- a. alimenter en un immunoadsorbant comprenant une phase solide sur laquelle sont fixés en quantités approximativement égales polypeptide pG2 et polypeptide 121 d'HTLV-III;
- b. incubier l'immunoadsorbant avec un échantillon de fluide biologique;
- c. séparer l'immunoadsorbant de l'échantillon; et
- d. incubier l'immunoadsorbant avec une solution d'anticorps anti-Ig humain ;
- e. séparer l'immunoadsorbant de l'échantillon; et
- f. déterminer la fixation de l'anticorps sur l'immunoadsorbant en tant qu'indication de l'anticorps contre l'HTLV-III dans l'échantillon.

8. Immunoadsorbant tel que défini à la revendication 7, ledit immunoadsorbant comprenant une phase solide enduite d'une quantité égale de polypeptide pG2 et de polypeptide 121.

9. Antigène de noyau d'HTLV-III recombinant immunoréactif avec un anticorps contre les protéines de noyau d'HTLV-III, ledit antigène de noyau étant tel défini à la revendication 1 et pouvant être mis en oeuvre dans le procédé selon la revendication 1.

10. Polypeptide pG2, ledit polypeptide pouvant être mis en oeuvre dans le procédé selon l'une quelconque des revendications 1 à 4 ou l'un des tests selon l'une des revendications 6 ou 7.

11. Préparation pratiquement homogène de protéines pG2, ladite préparation pouvant être mise en oeuvre dans le procédé selon l'une quelconque des revendications 1 à 4 ou l'un des tests selon l'une des revendications 6 ou 7.

#### Revendications pour l'Etat contractant suivant : AT

1. Procédé de détection d'anticorps contre les protéines de noyau d'HTLV-III dans un fluide biologique (tel que le plasma ou le sérum humain) comprenant les étapes suivantes :

- a. alimenter en un immunoadsorbant d'antigène comprenant une phase solide sur laquelle est fixée un antigène de noyau d'HTLV-III qui est un antigène chimérique comprenant une séquence aminoacide commençant de l'acide 1 au 99 et s'étendant jusqu'au numéro 228 de la séquence aminoacide, de la forme représentée à la figure 5, l'antigène chimérique étant immunoréactif par rapport à l'anticorps contre les protéines de noyau d'HTLV-III;
- b. incubier l'immunoadsorbant avec un échantillon du fluide biologique à tester, dans des conditions permettant à l'anticorps dans l'échantillon de se complexer avec l'immunoadsorbant d'antigène;
- c. séparer l'immunoadsorbant de l'échantillon ; et
- d. déterminer la fixation de l'anticorps sur l'immunoadsorbant, en tant qu'indication de l'anticorps contre les protéines de noyau d'HTLV-III dans l'échantillon.

2. Procédé selon la revendication 1, dans lequel l'étape de détermination de la fixation de l'anticorps sur l'immunoadsorbant comprend elle-même les étapes suivantes :

- a. incubier l'immunoadsorbant avec un anticorps marqué, contre l'immunoglobuline de l'espèce dont dérive le fluide biologique (tel l'anticorps anti-Ig humaine dans le cas du plasma ou du sérum humain);
- b. séparer l'immunoadsorbant de l'anticorps marqué; et
- c. détecter le marqueur associé à l'immunoadsorbant en tant qu'indication de l'anticorps contre les protéines de noyau d'HTLV-III dans l'échantillon.

3. Procédé selon l'une des revendications 1 ou 2 dans lequel les protéines de noyau d'HTLV-III sont le polypeptide pG2 présentant une séquence aminoacide essentiellement de la forme représentée à la figure 5.

4. Procédé de détection d'anticorps contre les protéines de noyau d'HTLV-III dans le sérum ou le plasma humain selon l'une quelconque des revendications 1 à 3 comprenant les étapes suivantes :

- a. alimenter en un immunoadsorbant d'antigène comprenant une granule de polystyrène enduite d'une préparation purifiée pratiquement homogène de polypeptide pG2;



- b. incuber l'immunoabsorbant avec un échantillon de sérum ou de plasma humain dans des conditions qui permettent à l'anticorps contre les protéines de noyau d'HTLV-III dans l'échantillon, de se complexer avec le polypeptide pG2;
- c. séparer l'immunoabsorbant de l'échantillon;
- 5 d. incuber l'immunoabsorbant avec une solution d'anticorps marqué anti-Ig humaine;
- e. séparer l'immunoabsorbant de la solution d'anticorps marqué; et
- f. détecter le marqueur associé à l'immunoabsorbant en tant qu'indication de l'anticorps contre les protéines de noyau d'HTLV-III dans l'échantillon.
- 10 5. Procédé de production d'un immunoabsorbant comprenant la fixation sur une phase solide de support, de protéines de noyau d'HTLV-III qui sont un antigène chimérique tel que défini dans l'une quelconque des revendications précédentes.
6. Test pour anticorps contre l'HTLV-III dans un fluide biologique comprenant les étapes suivantes :
- a. alimenter en un immunoabsorbant comprenant une phase solide sur laquelle est fixé un mélange de protéines de noyau d'HTLV-III recombinées telles que définies dans l'une quelconque des revendications
- 15 précédentes, lesdites protéines de noyau étant immunoréactives avec l'anticorps contre les protéines de noyau d'HTLV-III, mélange comprenant également des protéines d'enveloppe d'HTLV-III recombinantes immunoréactives avec un anticorps contre les protéines d'enveloppe d'HTLV-III;
- b. incuber l'immunoabsorbant avec un échantillon de fluide biologique;
- c. séparer l'immunoabsorbant de l'échantillon; et
- 20 d. déterminer la fixation de l'anticorps sur l'immunoabsorbant en tant qu'indication de l'anticorps contre l'HTLV-III dans l'échantillon.
7. Test pour les anticorps contre l'HTLV-III dans un fluide biologique selon la revendication 6 comprenant les étapes suivantes :
- a. alimenter en un immunoabsorbant comprenant une phase solide sur laquelle sont fixés en quantités
- 25 approximativement égales polypeptide pG2 et polypeptide 121 d'HTLV-III;
- b. incuber l'immunoabsorbant avec un échantillon de fluide biologique;
- c. séparer l'immunoabsorbant de l'échantillon; et
- d. incuber l'immunoabsorbant avec une solution d'anticorps anti-Ig humain ;
- e. séparer l'immunoabsorbant de l'échantillon; et
- 30 f. déterminer la fixation de l'anticorps sur l'immunoabsorbant en tant qu'indication de l'anticorps contre l'HTLV-III dans l'échantillon.
8. Immunoabsorbant tel que défini à la revendication 7, ledit immunoabsorbant comprenant une phase solide enduite d'une quantité égale de polypeptide pG2 et de polypeptide 121.

35


40

45

50

55

FIGURE 1







FIGURE 3







FIGURE 5

33 amino acids from REV vector

CCAGAATGGGA  
AlaGluIrpAsp

TAGAATACATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAATGACATAOCAGO  
 ArgValHisProValHisAlaGlyProIleAlaProGlyGlnMetArgGluProArgGlySerAspIleAlaGly

AACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCCCAGTAGGAGAAAATTTATAA  
 ThrThrSerThrLeuGlnGluGlnIleGlyIrpMetThrAsnAsnProProIleProValGlyGluIleTyrLys

AAGATGGATAATCCTGGATTAAATAAAATAGTAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAAGO  
 ArgIrpIleIleLeuGlyLeuAsnLysIleValArgMetIrpSerProThrSerIleLeuAspIleArgGlnGly

ACCAAAAGAACCTTTTAGAGACTATGTAGACCGTTCTATAAACTCTAAGAGCCGAGCAAGCTTCACAGGAGOT  
 ProLysGluProPheArgAspIrpValAspArgPheIrpLysIrpLeuArgAlaGluGlnAlaSerGlnGluVal

AAAAAATTGGATGACAGAAACCTTGTGCTCCAAATGCGAACCAGATTGTAAGACTATTTTAAAGCATTGGG  
 LysAsnIrpMetThrGluThrLeuLeuValGlnAsnAlaAsnProAspCysLysThrIleLeuLysAlaLeuGly

ACCAGCGGTACACTAGAAGAAATGATGACAGCATGTCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGATTTT  
 ProAlaAlaThrLeuGluGluMetMetThrAlaCysGlnGlyValGlyGlyProGlyHisLysAlaArgValLeu

GGCTGAAGCAATGAGCCAAOTAACAAATACAGCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAAGAAA  
 AlaGluAlaMetSerGlnValThrAsnThrAlaThrIleMetMetGlnArgGlyAsnPheArgAsnGlnArgLys

CATGGTTAAGTGTTCATTTGTGGCAAAGAAGGGCACACAGCCAGAAATTCAGGGCCCCCTAGGAAAAAGGGCTG  
 MetValLysCysPheAsnCysGlyLysGluGlyHisThrAlaArgAsnCysArgAlaProArgLysLysGlyCys

TTGAAAATGTGAAAAGGAGGACACCAAAATGAAAATTTACTGAGAGACAGGCTAAATTTTTAGGGAATC  
 TrpLysCysGlyLysGluGlyHisGlnMetLysAspCysThrGluArgGlnAlaAsnPheLeuGlyLysIle

14 amino acids from REV vector

FIGURE 6

